EGFR and non-small cell lung carcinoma: The superiority of afatinib in terms of PFS and responses over pemetrexed plus cisplatin [68] or gemcitabine plus cisplatin [69] for patients with EGFR-mutant NSCLC was demonstrated in two clinical trials.